Biocatalysis Patents: Who Leads, Where the Gaps Are 2026
- Filing has cooled since 2018. the peak year at 22 records, against 10 at the 2017 start and a flat-to-declining midpoint of 10 in 2022 — this is not a growing field on paper.
- 37.9% of all 190 records sit with five assignees. and 55.3% with ten, so most of the remaining 79 ranked companies hold only one or two families each.
- Immobilization and cofactor chemistry carry the oldest, most-cited claims. several of the most-cited records date to the 1990s and 2000s and still anchor freedom-to-operate checks today.
What the biocatalysis patent record shows
The dataset covers 190 published patent records filed against a search built around biocatalysis, enzymatic transformation and industrial enzyme catalysis, cross-referenced with enzyme engineering, immobilization, cofactor regeneration, solvent tolerance and process mass intensity, and bounded to IPC classes C12P7, C12N9 and C12N11. The window runs from 2015 through the 2026-07-31 cut-off, so the most recent year is necessarily undercounted — publication typically lags filing by around 18 months.
Read as patent families rather than raw filings, the picture is one of an established, moderately consolidated field rather than an emerging one. Filing activity peaked in 2018 and has not recovered since, while a small group of assignees holds a disproportionate share of the record base — a pattern worth checking before committing to a filing strategy in the same claim space.
Filing trend and technology composition
Two views of the same 190 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
A field that peaked in 2018 and has not recovered
Filings ran from 10 in 2017 to a peak of 22 in 2018, then eased back toward a flat midpoint of 10 by 2022. The 2026 figure of 0 reflects the data cut-off rather than a stop in activity — treat the last one to two years as understated pending publication lag.
Microorganism and fermentation classes dominate
C12N (microorganisms and genetic engineering) appears on 92.6% of the 190 records and C12P (fermentation and enzymatic synthesis) on 57.4%, confirming the search is anchored where expected. Smaller but recurring overlaps into C07K peptides (13.7%), A61K medicinal preparations (7.9%), G01N testing (6.8%) and C11D detergents (5.8%) mark the adjacent application areas where enzyme claims are being repurposed.
Shares are the percentage of the 190 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biocatalysis and Enzymatic Transformation with Eureka
This page is one run against one query. Ask Eureka your own question about biocatalysis and enzymatic transformation and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records anchor immobilization and solvent-tolerant catalysis
Molecule immobilization method and its system (US20140342429A1)
A method for immobilizing macromolecules, including biomolecules, onto a solid carrier to form a bioreactor: a leading molecule links to the biomolecule via microwave treatment to form an adsorbent, which is then mixed with a porous support material and processed by vortex so the adsorbent adsorbs and immobilizes onto the support, producing a reusable bioreactor for biological reactions and biocatalysis.Filed by Chung Yuan Christian University, 2014-11-20.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6042824A | Methods using crosslinked protein crystal formulations as catalysts in organic solvents | 52 |
| 2 | US5932212A | Crosslinked protein crystal formulations and their use as catalysts in organic solvents | 38 |
| 3 | WO2005056808A2 | Immobilization of biocatalysts by template-directed silicate precipitation | 34 |
| 4 | WO1997044445A1 | Cross-linked protein crystal formulations and their use as catalysts in organic solvents | 31 |
| 5 | US20170067084A1 | Production of chiral 1,2-amino alcohols and alpha-amino acids from alkenes by cascade biocatalysis | 29 |
| 6 | US20200131650A1 | Engineered electrode for electrobiocatalysis and process to construct the same | 28 |
| 7 | US20050019882A1 | Plant enzymes for bioconversion | 28 |
| 8 | US20150087044A1 | Polyhedral cage-containing mesoporous metal-organic frameworks as platform for biocatalysis, methods of makin… | 21 |
| 9 | US20050158837A1 | Immobilization of biocatalysts by template-directed silicate precipitation | 19 |
| 10 | US9617573B2 | Engineered transaminase polypeptides for industrial biocatalysis | 18 |
Citation counts favour older records within the searched corpus — read them as a signal of influence on later filings, not as a measure of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that change how a team should read this space before drafting claims or scoping freedom-to-operate.
Claim space is held by a narrow group
Five assignees account for 37.9% of all 190 records in scope, and ten account for 55.3%. The other 79 ranked companies in the assignee list generally hold only a handful of families each, which points to a long tail of single-jurisdiction or single-application filers rather than sustained programmes.
Activity has flattened since the 2018 peak
Filings rose to 22 in 2018 from 10 the year before, then settled back to a flat 10 by the 2022 midpoint. Several of the most active historical assignees show 0 filings and a -100% year-over-year change in the latest tracked year, consistent with mature programmes rather than active expansion.
Enzyme claims are spreading into detergents and pharma formulation
Beyond the core C12N/C12P classes, a consistent minority of records also carry C11D detergent-composition classes and A61K medicinal-preparation classes, showing enzyme engineering claims being repurposed into cleaning products and drug manufacturing rather than staying confined to fermentation process claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biocatalysis and enzymatic transformation, with the prior art for and against each one.
Who is active, and where the field is still open
The ranked assignee list spans 89 companies and research institutions. Most of the activity by volume sits with a small set of industrial biocatalysis specialists and pharmaceutical and academic filers, while momentum data shows several of the historically largest filers now inactive in the most recent tracked year.
A single filer leads the ranking outright
The top-ranked assignee holds 36 records, well ahead of the fifth-place holder at 8 and the tenth-place holder at 6 — a steep drop-off that marks this as a leader-plus-long-tail structure rather than a evenly distributed field.
Former leaders have gone quiet
More than one of the assignees with the largest historical filing counts recorded 0 filings in the latest tracked year, a -100% year-over-year change. That does not necessarily mean exit from the field — granted portfolios may simply be maintained rather than expanded — but it does mean the newest competitive activity is not coming from the incumbents.
Collaboration is limited and mostly institutional
Only 10 co-assignee pairs appear across the dataset, and the strongest of these link an industrial partner with an academic or public-research partner, or two public research bodies together — a pattern typical of translational biocatalysis work rather than joint-venture commercial filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Codexis, Inc. | 0 | -100% |
| Novartis AG | 0 | -100% |
| Evonik Operations GmbH (Degussa) | 0 | — |
| Altus Pharmaceuticals Inc. | 0 | — |
| Genencor International, Inc. | 0 | — |
| Gecco Biotech BV | 0 | — |
| Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA) | 0 | — |
| Dow Silicones Corporation | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking or claim drafting.
Check freedom-to-operate against the oldest cited records
The highest-cited records in this set date to the 1990s and 2000s and cover crosslinked protein crystal catalysts and template-directed immobilization — claims that may still be live and worth a dedicated search before filing in the same mechanical approach.
Run a freedom-to-operate search in EurekaTrack the quiet incumbents for renewed activity
Several of the largest historical filers show 0 filings and negative year-over-year momentum in the latest tracked period. A renewed filing from any of them would be an early signal worth monitoring rather than assuming permanent exit.
Set up assignee monitoring in EurekaDraft into the identified under-claimed branches
Cofactor regeneration in continuous-flow formats and solvent-tolerant variant engineering show comparatively low filing density against the core immobilization and fermentation classes, which is where a first claim is more likely to clear prior art cleanly.
Explore white space mapping in EurekaCommon questions about biocatalysis patents
Within this 190-record dataset spanning 2015 through the 2026-07-31 cut-off, filings peaked at 22 in 2018 and had eased back to a flat 10 by the 2022 midpoint. The 2025-2026 figures show near zero, but that reflects publication lag rather than an actual stop in filing activity, since publication typically trails the original filing date by around 18 months. Anyone tracking this space should treat the most recent one to two years as an undercount until later data cuts catch up.
The ranked assignee list covers 89 companies and institutions, with the top-ranked filer holding 36 records against 8 at fifth place and 6 at tenth — a steep drop that marks a leader-plus-long-tail structure. Combined, the five leading assignees account for 37.9% of all 190 records in scope, and the leading ten account for 55.3%. The remaining ranked companies typically hold only a handful of families each, so most competitive activity by volume sits with a small group.
Not on this evidence. Filing activity rose from 10 records in 2017 to a peak of 22 in 2018, then declined to a flat 10 by 2022, and several of the historically largest filers recorded zero filings and a -100% year-over-year change in the most recent tracked year. High historical filing density in the core immobilization and fermentation classes means claim space there is occupied, though that is a statement about crowding, not about whether the underlying science has matured or stalled.
The core IPC classes, C12N microorganism and genetic-engineering claims at 92.6% of records and C12P fermentation and enzymatic-synthesis claims at 57.4%, are heavily occupied. Lower-density adjacent areas, including cofactor regeneration under continuous-flow conditions, solvent-tolerant enzyme variants for non-aqueous media, and enzyme-detergent formulation stability, appear far less often relative to that core and are worth a closer prior-art check before assuming they are unavailable. Cascade biocatalysis routes to chiral amino alcohols also show up among the most-cited records, suggesting active but not yet saturated interest.
US20140342429A1, filed by Chung Yuan Christian University in 2014, claims a method of immobilizing biomolecules onto a porous solid support using a microwave-linked adsorbent step followed by vortex-based adsorption, producing a reusable bioreactor for biocatalytic reactions. It is one specific mechanical route to immobilization, not a claim over immobilization generally, so it would only block approaches that use the same microwave-linking-plus-vortex sequence onto a porous carrier. Teams using different immobilization chemistries, such as covalent crosslinking or silicate-based encapsulation referenced elsewhere in the most-cited records, would need to check those claims separately rather than assume this one covers the field.
Research Biocatalysis and Enzymatic Transformation in depth with Eureka
Go past this page: query the whole biocatalysis and enzymatic transformation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.